Navigation Links
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
Date:11/5/2009

SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced financial results for its third quarter and nine months ended Sept. 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Third Quarter and Nine Months 2009 Financial Results

Revenue for the third quarter and nine months ended Sept. 30, 2009, was $4.5 million and $12.8 million, respectively, compared with $3.8 million and $12.2 million, respectively, in 2008. Revenues were primarily earned through Trubion's strategic collaborations with Pfizer Inc. and Facet Biotech Corporation (announced Aug. 28, 2009).

Of the $12.8 million in revenue Trubion recognized during the first nine months of 2009, $8.5 million was collaborative research funding from the Pfizer collaboration and $3.6 million for recognition of the $40 million upfront fee received from Wyeth prior to its acquisition by Pfizer. Revenue earned in the nine months ended Sept. 30, 2009, also included $643,000 that was earned through the Facet collaboration. This is composed of $191,000 for recognition of the $20 million upfront fee and $1.4 million equity premium, and $452,000 in collaborative research funding.

This is compared with revenue of $12.2 million recognized in the first nine months of 2008, which was composed of $8.1 million for collaboration research funding from the Pfizer collaboration and $4.1 million for recognition of the $40 million upfront fee paid by Wyeth prior to its acquisition by Pfizer.

Total operating expenses for the third quarter and first
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
2. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
3. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
6. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
8. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
11. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... TAIPEI , 1. September 2015 ... Marksteins von 2.500 Mitarbeitern hat die SHL Group ... ein konstantes und rapides Wachstum auf dem ... Engagement, die Produktivität und das Management von SHL ... SHL ist weltweit führend in Design ...
(Date:9/1/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... development and sale of broadly enabling, pressure cycling ... life sciences industry, today announced the publication of ... PCT Platform could play a significant role in ... is based on PCT,s unique ability to help ...
(Date:9/1/2015)... 1, 2015  Based on its recent ... Frost & Sullivan recognizes Pie Medical Imaging ... Sullivan Award for Technology Leadership. ... innovative and easy-to-use imaging solutions—its CAAS and ... quantitative results for cardiovascular diagnosis and treatment ...
Breaking Medicine Technology:SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 2Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 3Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 4Frost & Sullivan Applauds Pie Medical Imaging for Highly Innovative Quantitative Software for Cardiovascular Diagnosis 5
... Ltd today announced that the National University Hospital (NUH), ... IRB equivalent) provisional approval for a new study: ... /DIEP Flap - Comparison of TIGR (100% Resorbable) vs ... randomized study, involving 86 patients. There are plans to ...
... Sept. 13 Three people living with diabetes can realize ... Bayer Diabetes Care,s "Give Back. Simply Win." Contest. Sponsored by ... on people with diabetes who are making a difference in ... Nick Jonas and a donation by Bayer of $5,000 to ...
Cached Medicine Technology:National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study 2Nick Jonas and Bayer Diabetes Care Enable Winners of the 'Give Back. Simply Win.' Contest to Realize Their Dream to Help Others 2Nick Jonas and Bayer Diabetes Care Enable Winners of the 'Give Back. Simply Win.' Contest to Realize Their Dream to Help Others 3
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy ... been named to the Inc. 5000 List, an independent ranking of the ... for 34 years, and this achievement puts Canopy in rarefied company. Over the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Traveling to the Caribbean ... array of magnificent flora and fauna. , Lifestyle Holidays Vacation Club knows ... To help make travelers experience that much better, Lifestyle Holidays Vacation Club has put ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate Cancer ... affects more than 233,000 men each year in the United States. , Prostate cancer ... non-skin cancer in America, affecting 1 in 7 men. One new case occurs every ...
(Date:9/1/2015)... ... ... Earth Brands, ( http://www.earthbrands.com ) a comfort-meets-fashion women’s footwear ... an Earth Brand shoe will be given an opportunity to plant a tree ... nonprofit dedicated to planting more trees. Earth Brands products represent contemporary designs and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes ... created from everyday life changes can lead to very serious, life-altering events. Fortunately ... coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses ...
Breaking Medicine News(10 mins):Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3
... San Diego, California, May 19, 2008 NPS Pharmaceuticals, ... 3 data at the annual Digestive Disease Week (DDW) ... may reduce dependence upon parenteral nutrition (PN) in patients ... (SBS). , The Phase 3 study evaluated ...
... counties - Los Angeles, Alameda, Contra Costa, San Mateo, San Francisco, ... ... Procedures, WOODLAND HILLS, Calif., May 19 ... initiative into California. Now, approximately 1.8 million of,Anthem Blue Cross members in ...
... of developing reliable genetic tests to guide lung cancer ... University recently evaluated the ability of five high-risk genetic ... would recur in patients whose non-small cell lung cancer ... their findings at the American Thoracic Societys 2008 International ...
... 19 Towards the Electronic,Patient Record (TEPR) ... terminology,announced today its next-generation interface terminology delivery ... access to all of,IMO,s terminology knowledge sources. ... optimized for millisecond response times in a ...
... Million Verdict Upheld Against Mesothelioma Victim,s Former Employers, ... fifteen months after,winning a $3.2 million verdict against ... Constructors, Inc. on behalf of,mesothelioma victim Ray Rando, ... been affirmed by the Louisiana First Circuit Court ...
... surgeon at the University of Liverpool has performed a groundbreaking ... more commonly seen in dogs. , The three year-old chimp ... year and now lives in a chimpanzee reserve supported by ... and had difficulty walking because a bone in her forearm ...
Cached Medicine News:Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 3Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 4Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 2Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 3Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 4Health News:Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd 2Health News:Surgeon operates to rescue chimp with rare deformity 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: